The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients

American Journal of Gastroenterology

Volumn 102, Issue 4, 2007, Pages 794-802

  Feagan, Brian G ^a   Reinisch, Walter ^b   Rutgeerts, Paul ^c   Sandborn, William J ^d   Yan, Songkai ^e   Eisenberg, Debra ^e   Bala, Mohan ^e   Johanns, Jewel ^e   Olson, Allan ^e   Hanauer, Stephen B ^f  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c Division of Gastroenterology   (Belgium)

^d MAYO CLINIC   (United States)

^e CENTOCOR INC   (United States)

^f UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; AZATHIOPRINE; CORTICOSTEROID; INFLIXIMAB; MERCAPTOPURINE; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG DOSE COMPARISON; DRUG EFFECT; FEMALE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SHORT FORM 36; ULCERATIVE COLITIS;

ADULT; ANTIBODIES, MONOCLONAL; CHI-SQUARE DISTRIBUTION; COLITIS, ULCERATIVE; DOUBLE-BLIND METHOD; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; MALE; PLACEBOS; QUALITY OF LIFE; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 33947709456     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2007.01094.x     Document Type: Article

References (24)

1. Bernklev T, Jahnsen J, Lygren I, et al. Health-related quality of life in patients with inflammatory bowel disease measured with the Short Form-36: Psychometric assessments and a comparison with general population norms. Inflamm Bowel Dis 2005;11:909-18.
2. Casellas F, Arenas JI, Baudet JS, et al. Impairment of health-related quality of life in patients with inflammatory bowel disease: A Spanish multicenter study. Inflamm Bowel Dis 2005;11:488-96.
3. Present D, Meltzer S, Krumholz M, et al. 6-Mercaptopurine in the management of inflammatory bowel disease: Short and long term toxicity. Ann Intern Med 1989;111:641-9.
4. Buchman A. Side effects of corticosteroid therapy. J Clin Gastroenterol 2001;33:289-94.
5. Brown E, Khan D, Nejtek V. The psychiatric side effects of corticosteroids. American College of Allergy, Asthma and Immunology 1999;83:495-504.
6. Murch SH, Lamkin VA, Savage MO, et al. Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut 1991;32:913-7.
7. Murch SH, Braegger CP, Walker-Smith JA, et al. Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut 1993;34:1705-9.
8. Braegger CP, Nicholls S, Murch SH, et al. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992;339:89-91.
9. Shen E, Das K. Current therapeutic recommendations: Infliximab for ulcerative colitis. J Clin Gastroenterol 2004;38:741-5.
10. Gerloni V, Pontikaki I, Gattinara M, et al. Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor [alpha] monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis: Results of an open-label prospective study. Arthritis Rheum 2005;52:548-53.
11. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76.
12. Turnbull GK, Vallis TM. Quality of life in inflammatory bowel disease: The interaction of disease activity with psychosocial function. Am J Gastroenterol 1995;90:1450-4.
13. Ware E, Sherbourne C. The MOS-36 item short-form health survey (SF-36): I. Conceptual framework and item selection. Med Care 1992;30:473-83.
14. Irvine EJ, Feagan B, Rochon J, et al. Quality of life: A valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology 1994;106:287-96.
15. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987;317:1625-9.
16. Pallis A, Vlachonikolis I, Mouzas I. Assessing health-related quality of life in patients with inflammatory bowel disease, in Crete, Greece. BioMed Central Gastroenterol 2002;2:1-15.
17. Guyatt G, Mitchell A, Irvine E, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989;96:804-10.
18. Gregor JC, McDonald JWD, Klar N, et al. An evaluation of the utility measurement in Crohn's disease. Inflamm Bowel Dis 1997;3:265-76.
19. Irvine EJ. Development and subsequent refinement of the Inflammatory Bowel Disease Questionnaire: A quality-of-life instrument for adult patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1999;28(suppl 4):S23-7.
20. Ware J, Kosinski M, Keller S. SF-36 physical and mental health summary scales: A user's manual, 4th Ed. Boston, MA: The Health Institute, 1994.
21. Samsa G, Edelman D, Rothman ML, et al. Determining clinically important differences in health status measures: A general approach with illustration to the Health Utilities Index Mark II. Pharmacoeconomics 1999;15:141-55.
22. Rubin GP, Hungin APS, Chinn DJ, et al. Quality of life in patients with established inflammatory bowel disease: A UK general practice survey. Aliment Pharmacol Ther 2004;19:529-35.
23. Alonso J, Ferrer M, Gandek B, et al. Health-related quality of life associated with chronic conditions in eight countries: Results from the International Quality of Life Assessment (IQOLA) Project. Qual Life Res 2004;13:283-98.
24. van der Eijk I, Vlachonikolis IG, Munkholm P, et al. The role of quality of care in health-related quality of life in patients with IBD. Inflamm Bowel Dis 2004;10:392-8.